Skip to main content
OpenTrials
Completed

NCT Number: NCT02690740

Titrated Quantitative Conjunctival Provocation Test (tqCPT)

The clinical relevance of an allergen-specific sensitization is proven e.g., by allergen challenge tests in clinical routine. Several protocols for different challenge tests such as nasal (NPT), bronchial (BPT) or conjunctival provocation test (CPT) have been proposed. Beneath others, the CPT is broadly used in both clinical trials and routine because of its feasibility.

However, there is no internationally harmonized standard regarding the clinical interpretation of CPT results as well as a lack of validation of a specific outcome score. Therefore, this trial aims to investigate and validate a new scoring system for CPT results in order to provide this test as a useful method in future clinical trials.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Of 33 patients who had been initially screened, ten patients did not fulfill all of the inclusion criteria mentioned hereafter. Thus, 23 patients aged 18 to 67 years having a birch and/or grass pollen allergy were included in the analysis. The study is in line with the Declaration of Helsinki and is approved by the responsible ethics committee (FF 118/2012 (4 December 2012); Landesärztekammer Hessen, Frankfurt, Germany). All participating patients are informed of the nature and objectives of the study and signed an informed consent document.

The CPT is conducted using standardized and registered allergen extracts (ALK- Abelló, Hørsholm, Denmark). At the first visit, a titrated quantitative CPT (tqCPT) is performed according to a standardized protocol. In case of a positive test result, CPT-results are to be confirmed at a re-challenge one week later. The final CPT takes place 3 to 4 weeks after the 2nd (confirmatory) challenge for analyzing the primary objective of the trial: reproducibility of the CPT symptom score. Furthermore, objective evaluation of the clinical reactions after the tqCPT is documented using a MATLAB software program to calculate the degree of redness in percent. This is then correlated with the (subjective) main investigators' evaluations and with the external observer's evaluations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • moderate to severe allergic rhinoconjunctivitis (ARC) symptoms in preceding two years -intake of anti-allergic medication in the preceding two years -positive test result in skin prick test (SPT) (wheal size at least 3 mm larger than the negative control). -
  • retrospective global symptoms score (≥5 out of 12)

Exclusion criteria

  • acute diseases of the eye or of the nose/nasal sinuses,
  • persistent allergy
  • intake of concomitant (antiallergic) medication prior to CPT-challenges
  • CPT score ≥3 during the examination of the control (non-challenged eye) at baseline

Treatment and study plan

(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml

Other

see information in "arm/group descriptions"

Primary outcomes

  1. total conjunctival symptoms provoked by conjunctival provocation test (CPT) at two consecutive settings

    Time frame: baseline and re-challenge after 3-4 weeks

    Total Conjunctival symptoms (itching (0-3), irritation (0-3), tearing (0-3), redness (0-3)) provoked by a conjunctival provocation test (CPT) were evaluated and categorized on a 4 point Likert-Scale (Total Score = 0-12 points)) at a first setting and then again after a rechallenge after an interval of 3-4 weeks. Changes of Total score values (0-12 points) of both settings were calculated using the the Pearson and Spearman correlation coefficients.

Secondary outcomes

  1. Conjunctival redness score (0-3) provoked by conjunctival provocation test (CPT) at two consecutive settings.

    Time frame: baseline and re-challenge after 3-4 weeks

    Conjunctival redness provoked by a conjunctival provocation test (CPT) was evaluated and categorized on a 4 point Likert-Scale (0-3) at a first setting and then again after a rechallenge after an interval of 3-4 weeks. Changes of the conjunctival redness score of both settings were calculated using the the Pearson and Spearman correlation coefficients.

  2. difference in the degree of conjunctival redness provoked by conjunctival provocation test (CPT) at two consecutive settings as assessed by digital photo analysis

    Time frame: baseline and re-challenge after 3-4 weeks

    Degree of conjunctival redness provoked by conjunctival provocation test (CPT) was assessed by digital photo analysis at a first setting and then after a rechallenge of 3-4 weeks. The percent change in the redness area was determined by a special software program.

  3. Correlation of the degree of conjunctival redness as assessed by digital photo analysis with the conjunctival redness score evaluated and categorized on a 4 point Likert-Scale (0-3) provoked by a conjunctival provocation test (CPT).

    Time frame: baseline and re-challenge after 3-4 weeks

Sponsors and collaborators

Lead sponsor

Zentrums für Rhinologie und Allergologie Wiesbaden

Other

Collaborators

  • University Hospital of Cologne

Registry information

Official study title

Titrated Quantitative Conjunctival Provocation Test (tqCPT): Standardization and Validation of a New Clinical Endpoint

Acronym: tqCPT

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Feb 24, 2016
Registry last updated
Feb 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.